

**TOXICOLOGICAL PROFILE FOR
1,2-DICHLOROETHANE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

September 2001

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.


 Jeffrey P. Koplan, M.D., M.P.H.
 Administrator
 Agency for Toxic Substances and
 Disease Registry

Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepared toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by *type of health effect* (death, systemic, immunologic, reproductive), by *route of exposure*, and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Section 1.6	How Can (Chemical X) Affect Children?
Section 1.7	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-888-42-ATSDR or (404) 639-6357 **Fax:** (404) 639-6359
E-mail: atsdric@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoc.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Malcolm Williams, D.V.M., Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Stephen Bosch, M.S.
Mario Citra, Ph.D.
Syracuse Research Corporation, North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.

PEER REVIEW

A peer review panel was assembled for 1,2-dichloroethane. The panel consisted of the following members:

1. Dr. G.A. Shakeel Ansari, Department of Human Biological Chemistry & Genetics and Pathology, University of Texas Medical Branch, Galveston, TX;
2. Dr. John L. Egle, Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA;
3. Dr. F. Peter Guengerich, Center in Molecular Toxicology, Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN; and
4. Mr. Lyman K. Skory, Skory Consulting, Inc., Health, Environmental and Regulatory Consulting, Midland, MI.

These experts collectively have knowledge of 1,2-dichloroethane's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS 1,2-DICHLOROETHANE?	1
1.2 WHAT HAPPENS TO 1,2-DICHLOROETHANE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO 1,2-DICHLOROETHANE?	3
1.4 HOW CAN 1,2-DICHLOROETHANE ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN 1,2-DICHLOROETHANE AFFECT MY HEALTH?	4
1.6 HOW CAN 1,2-DICHLOROETHANE AFFECT CHILDREN?	6
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1,2-DICHLOROETHANE?	7
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,2-DICHLOROETHANE?	8
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	8
1.10 WHERE CAN I GET MORE INFORMATION?	10
2. RELEVANCE TO PUBLIC HEALTH	11
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,2-DICHLOROETHANE IN THE UNITED STATES	11
2.2 SUMMARY OF HEALTH EFFECTS	12
2.3 MINIMAL RISK LEVELS	18
3. HEALTH EFFECTS	21
3.1 INTRODUCTION	21
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	21
3.2.1 Inhalation Exposure	23
3.2.1.1 Death	37
3.2.1.2 Systemic Effects	38
3.2.1.3 Immunological and Lymphoreticular Effects	44
3.2.1.4 Neurological Effects	45
3.2.1.5 Reproductive Effects	46
3.2.1.6 Developmental Effects	47
3.2.1.7 Cancer	48
3.2.2 Oral Exposure	49

3.2.2.1	Death	50
3.2.2.2	Systemic Effects	72
3.2.2.3	Immunological and Lymphoreticular Effects	79
3.2.2.4	Neurological Effects	80
3.2.2.5	Reproductive Effects	82
3.2.2.6	Developmental Effects	82
3.2.2.7	Cancer	83
3.2.3	Dermal Exposure	86
3.2.3.1	Death	86
3.2.3.2	Systemic Effects	86
3.2.3.3	Immunological and Lymphoreticular Effects	87
3.2.3.4	Neurological Effects	87
3.2.3.5	Reproductive Effects	87
3.2.3.6	Developmental Effects	87
3.2.3.7	Cancer	87
3.3	GENOTOXIC EFFECTS	87
3.4	TOXICOKINETICS	94
3.4.1	Absorption	95
3.4.1.1	Inhalation Exposure	95
3.4.1.2	Oral Exposure	96
3.4.1.3	Dermal Exposure	97
3.4.2	Distribution	98
3.4.2.1	Inhalation Exposure	98
3.4.2.2	Oral Exposure	99
3.4.2.3	Dermal Exposure	100
3.4.2.4	Other Routes of Exposure	100
3.4.3	Metabolism	101
3.4.3.1	Inhalation Exposure	103
3.4.3.2	Oral Exposure	103
3.4.3.3	Intraperitoneal Exposure	104
3.4.3.4	Other Routes of Exposure	104
3.4.4	Elimination and Excretion	105
3.4.4.1	Inhalation Exposure	105
3.4.4.2	Oral Exposure	106
3.4.4.3	Dermal Exposure	107
3.4.4.4	Other Routes of Exposure	108
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	108
3.5	MECHANISMS OF ACTION	111
3.5.1	Pharmacokinetic Mechanisms	111
3.5.2	Mechanisms of Toxicity	112
3.5.3	Animal-to-Human Extrapolations	113
3.6	ENDOCRINE DISRUPTION	114
3.7	CHILDREN'S SUSCEPTIBILITY	114
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	119
3.8.1	Biomarkers Used to Identify or Quantify Exposure to 1,2-Dichloroethane	120
3.8.2	Biomarkers Used to Characterize Effects Caused by 1,2-Dichloroethane	121
3.9	INTERACTIONS WITH OTHER CHEMICALS	122
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	125
3.11	METHODS FOR REDUCING TOXIC EFFECTS	126
3.11.1	Reducing Peak Absorption Following Exposure	127

3.11.2	Reducing Body Burden	127
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	128
3.12	ADEQUACY OF THE DATABASE	129
3.12.1	Existing Information on Health Effects of 1,2-Dichloroethane	129
3.12.2	Identification of Data Needs	131
3.12.3	Ongoing Studies	151
4.	CHEMICAL AND PHYSICAL INFORMATION	153
4.1	CHEMICAL IDENTITY	153
4.2	PHYSICAL AND CHEMICAL PROPERTIES	153
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	157
5.1	PRODUCTION	157
5.2	IMPORT/EXPORT	157
5.3	USE	160
5.4	DISPOSAL	160
6.	POTENTIAL FOR HUMAN EXPOSURE	161
6.1	OVERVIEW	161
6.2	RELEASES TO THE ENVIRONMENT	163
6.2.1	Air	163
6.2.2	Water	163
6.2.3	Soil	166
6.3	ENVIRONMENTAL FATE	166
6.3.1	Transport and Partitioning	166
6.3.2	Transformation and Degradation	168
6.3.2.1	Air	168
6.3.2.2	Water	168
6.3.2.3	Sediment and Soil	169
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	170
6.4.1	Air	170
6.4.2	Water	172
6.4.3	Sediment and Soil	174
6.4.4	Other Environmental Media	174
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	175
6.6	EXPOSURES OF CHILDREN	178
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	179
6.8	ADEQUACY OF THE DATABASE	179
6.8.1	Identification of Data Needs	180
6.8.2	Ongoing Studies	183
7.	ANALYTICAL METHODS	185
7.1	BIOLOGICAL MATERIALS	185
7.2	ENVIRONMENTAL SAMPLES	187
7.3	ADEQUACY OF THE DATABASE	192
7.3.1	Identification of Data Needs	193
7.3.2	Ongoing Studies	193
8.	REGULATIONS AND ADVISORIES	195
9.	REFERENCES	201

10. GLOSSARY 247

APPENDICES

A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS A-1

B. USER'S GUIDE B-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS C-1

D. INDEX D-1

LIST OF FIGURES

3-1. Levels of Significant Exposure to 1,2-Dichloroethane - Inhalation	33
3-2. Levels of Significant Exposure to 1,2-Dichloroethane - Oral	67
3-3. Proposed Pathways for 1,2-Dichloroethane Metabolism	102
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	110
3-5. Existing Information on Health Effects of 1,2-Dichloroethane	130
6-1. Frequency of NPL Sites with 1,2-Dichloroethane Contamination	162

LIST OF TABLES

3-1. Levels of Significant Exposure to 1,2-Dichloroethane - Inhalation	24
3-2. Levels of Significant Exposure to 1,2-Dichloroethane - Oral	51
3-3. Genotoxicity of 1,2-Dichloroethane <i>In Vivo</i>	89
3-4. Genotoxicity of 1,2-Dichloroethane <i>In Vitro</i>	92
4-1. Chemical Identity of 1,2-Dichloroethane	154
4-2. Physical and Chemical Properties of 1,2-Dichloroethane	155
5-1. United States Production of 1,2-Dichloroethane	158
5-2. Facilities that Produce, Process, or Use 1,2-Dichloroethane	159
6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,2-Dichloroethane	164
6-2. Estimated Population Exposure to 1,2-Dichloroethane Through Releases to Ambient Air From a Number of Specific Emission Sources	177
7-1. Analytical Methods for Determining 1,2-Dichloroethane in Biological Samples	186
7-2. Analytical Methods for Determining 1,2-Dichloroethane in Environmental Samples	188
8-1. Regulations and Guidelines Applicable to 1,2-Dichloroethane	196